You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

Article info

Article menu

Download PDFPDF

Case Report
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

Authors

  • Mehmet Asim Bilen Division of Cancer MedicineThe University of Texas MD Anderson Cancer Center Houston TX USA PubMed articlesGoogle scholar articles
  • Sumit K. Subudhi Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Unit 1374, 1155 Pressler Street 77030-3721 Houston TX USA PubMed articlesGoogle scholar articles
  • Jianjun Gao Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Unit 1374, 1155 Pressler Street 77030-3721 Houston TX USA PubMed articlesGoogle scholar articles
  • Nizar M. Tannir Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Unit 1374, 1155 Pressler Street 77030-3721 Houston TX USA PubMed articlesGoogle scholar articles
  • Shi-Ming Tu Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Unit 1374, 1155 Pressler Street 77030-3721 Houston TX USA PubMed articlesGoogle scholar articles
  • Padmanee Sharma Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Unit 1374, 1155 Pressler Street 77030-3721 Houston TX USA PubMed articlesGoogle scholar articles
  1. ↵f (713) 792-2830 (713) 745-1625 padsharma{at}mdanderson.org
View Full Text

Citation

Bilen MA, Subudhi SK, Gao J, et al
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
Journal for ImmunoTherapy of Cancer 2016;4:36. doi: 10.1186/s40425-016-0139-8

Publication history

  • Received March 10, 2016
  • Accepted May 23, 2016
  • First published June 21, 2016.
Online issue publication 
June 21, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.